Premium
Unrelated cord blood transplantation for second hemopoietic stem cell transplantation
Author(s) -
Isoyama Keiichi,
Ohnuma Kei,
Ikuta Koichiro,
Toyoda Yasunori,
Nakajima Fumiaki,
Yamada Kouichiro,
Nishihira Hirokazu
Publication year - 2003
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1046/j.1442-200x.2003.01717.x
Subject(s) - medicine , umbilical cord , transplantation , cord blood , hematopoietic stem cell transplantation , umbilical cord blood transplantation , haematopoiesis , stem cell , surgery , immunology , biology , genetics
Background: The Kanagawa Cord Blood Bank (KCBB) reports the treatment of 12 patients who received umbilical cord blood transplantation (CBT) from unrelated donors as their second hemopoietic stem cell transplantation (HSCT).Methods: Provided by the KCBB, between February 1997 and September 2000, 12 patients had unrelated CBT as a second HSCT. Six patients were male and six female; nine patients were in malignant, and three were in non‐malignant conditions. The median age of the patients was 7.9 years (range, 2.2−28.0), and the median bodyweight was 22.5 kg (12.0−55.0). The HLA‐A and ‐B serological and DR genotypical disparities between the patients and CBT donors were as follows: one patient was a 0‐mismatch, six were 1‐mismatches, and five were 2‐mismatches.Results: The median time between first and second HSCT was 14.0 months (1.0−47.0). The overall survival rate was 25.0%, three years after CBT (Kaplan−Meier estimate). Mortality after CBT as a second HSCT accounted for nine cases, six from infection and three from treatment‐related mortality other than infection.Conclusion: Cord blood transplantation offers the advantage of rapid availability, absence of donor risk, and possibly less HLA restriction. In these contexts, unrelated CBT should be considered as a source of HSCT for a second transplant.